Trials / Completed
CompletedNCT00959777
Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating DA-3031 (PEG-G-CSF) to Filgrastim (Dong-A) in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- Male
- Age
- 20 Years – 40 Years
- Healthy volunteers
- —
Summary
The safety, tolerability, and pharmacokinetics(PK)/pharmacodynamics (PD) of DA-3031 (PEG-G-CSF) following a single dose delivered by subcutaneous (SC) injection were investigated in healthy volunteers. PK/PD of filgrastim (Dong-A) following repeated dose delivered by SC injection were investigated in healthy volunteers. PK/PD from a single dose of DA-3031 and repeated dose of filgrastim (Dong-A) were compared.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DA-3031 | |
| DRUG | Filgrastim |
Timeline
- First posted
- 2009-08-17
- Last updated
- 2014-10-01
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00959777. Inclusion in this directory is not an endorsement.